JPI AMR, the Joint Programming Initiative on Antimicrobial Resistance, coordinates national public investments and funds transnational research and activities within the six priority areas of the shared JPI AMR Strategic Research and Innovation Agenda (SRIA) – therapeutics, diagnostics, surveillance, transmission, environment and interventions. JPIAMR seeks and supports solutions to decrease transmissions of resistant bacteria in order to lessen the burden of AMR on a global scale together with the 28 member countries.
- Link to JPI AMR website
- Rita Rinnankoski-Tuikka, Science Adviser, tel. +358 295 335 096
- Sirpa Nuotio, Senior Science Adviser, tel. +358 295 335 082
Our email addresses are in the format firstname.lastname(at)aka.fi.